

Cyrus V Desouza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/794446/publications.pdf>

Version: 2024-02-01

53
papers

1,675
citations

361045

20
h-index

288905

40
g-index

53
all docs

53
docs citations

53
times ranked

2345
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Islet Autoimmunity Is Highly Prevalent and Associated With Diminished β -Cell Function in Patients With Type 2 Diabetes in the GRADE Study. <i>Diabetes</i> , 2022, 71, 1261-1271. | 0.3 | 11 |
| 2 | KDIGO recommendations for the evaluation of glycemic control in advanced chronic kidney disease. <i>Kidney International</i> , 2022, 101, 420. | 2.6 | 4 |
| 3 | The effect of nonpharmaceutical weight loss interventions in rural patients with diabetes: REPOWER Diabetes. <i>Obesity</i> , 2022, 30, 884-892. | 1.5 | 0 |
| 4 | Myristic Acid Supplementation Aggravates High Fat Diet-Induced Adipose Inflammation and Systemic Insulin Resistance in Mice. <i>Biomolecules</i> , 2022, 12, 739. | 1.8 | 10 |
| 5 | Adrenal Insufficiency From Immune Checkpoint Inhibitors Masquerading as Sepsis. <i>JCO Oncology Practice</i> , 2021, 17, 212-214. | 1.4 | 7 |
| 6 | Effect of Behavioral Therapy With In-Clinic or Telephone Group Visits vs In-Clinic Individual Visits on Weight Loss Among Patients With Obesity in Rural Clinical Practice. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 363. | 3.8 | 36 |
| 7 | The Effectiveness of Adding Pharmacotherapy to Dietary Counseling for Veterans in a Veterans Health Administration Move! Weight Management Program. <i>Journal of the Endocrine Society</i> , 2021, 5, A38-A38. | 0.1 | 0 |
| 8 | Testing the Psychometric Characteristics of the Revised Mastery of Stress Instrument in Adults With Type 2 Diabetes. <i>Journal of Nursing Measurement</i> , 2021, , JNM-D-20-00137. | 0.2 | 0 |
| 9 | Results of a Study Comparing Glycated Albumin to Other Glycemic Indices. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 677-687. | 1.8 | 23 |
| 10 | A combination of Omega-3 PUFAs and COX inhibitors: A novel strategy to manage obesity-linked dyslipidemia and adipose tissue inflammation. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107494. | 1.2 | 10 |
| 11 | Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 543-556. | 1.8 | 24 |
| 12 | Lauric Acid versus Palmitic Acid: Effects on Adipose Tissue Inflammation, Insulin Resistance, and Non-Alcoholic Fatty Liver Disease in Obesity. <i>Biology</i> , 2020, 9, 346. | 1.3 | 30 |
| 13 | Implications of the Hemoglobin Glycation Index on the Diagnosis of Prediabetes and Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e130-e138. | 1.8 | 22 |
| 14 | Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs). <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001830. | 1.2 | 3 |
| 15 | SAT-347 Diagnosis of Autosomal Dominant Hypocalcemia Type 1 Following the Initiation of Imatinib for Treatment of Chronic Myeloid Leukemia. <i>Journal of the Endocrine Society</i> , 2020, 4, . | 0.1 | 1 |
| 16 | Quantifying vehicle control from physiology in type 1 diabetes. <i>Traffic Injury Prevention</i> , 2019, 20, S26-S31. | 0.6 | 4 |
| 17 | Altered motor dynamics in type 1 diabetes modulate behavioral performance. <i>NeuroImage: Clinical</i> , 2019, 24, 101977. | 1.4 | 5 |
| 18 | Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 515-527. | 5.5 | 180 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Driving Safety and Real-Time Glucose Monitoring in Insulin-Dependent Diabetes. <i>International Journal of Automotive Engineering</i> , 2019, 10, 34-40. | 0.3 | 21 |
| 20 | The impact of type 1 diabetes on neural activity serving attention. <i>Human Brain Mapping</i> , 2019, 40, 1093-1100. | 1.9 | 10 |
| 21 | Altered Brain Dynamics in Patients With Type 1 Diabetes During Working Memory Processing. <i>Diabetes</i> , 2018, 67, 1140-1148. | 0.3 | 27 |
| 22 | Implications of the CANVAS Study in Reducing Cardiovascular Outcomes. <i>Current Diabetes Reports</i> , 2018, 18, 142. | 1.7 | 1 |
| 23 | A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin. <i>Diabetes Care</i> , 2018, 41, 1926-1937. | 4.3 | 49 |
| 24 | Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2426-2434. | 2.2 | 11 |
| 25 | A retrospective review of insulin requirements in patients using U-500 insulin hospitalized to a Veterans Affairs Hospital. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 874-879. | 1.2 | 3 |
| 26 | A combination of dietary N-3 fatty acids and a cyclooxygenase-1 inhibitor attenuates nonalcoholic fatty liver disease in mice. <i>Journal of Nutritional Biochemistry</i> , 2017, 42, 149-159. | 1.9 | 4 |
| 27 | Nanoformulated copper/zinc superoxide dismutase exerts differential effects on glucose vs lipid homeostasis depending on the diet composition possibly via altered AMPK signaling. <i>Translational Research</i> , 2017, 188, 10-26. | 2.2 | 20 |
| 28 | At-Risk Driving Behavior in Drivers with Diabetes: A Neuroergonomics Approach. <i>Proceedings of the Human Factors and Ergonomics Society</i> , 2017, 61, 1881-1885. | 0.2 | 1 |
| 29 | Nanoformulated copper/zinc superoxide dismutase reduces adipose inflammation in obesity. <i>Obesity</i> , 2016, 24, 148-156. | 1.5 | 32 |
| 30 | Protocol for the Rural Engagement in Primary Care for Optimizing Weight Reduction (RE-POWER) Trial: Comparing three obesity treatment models in rural primary care. <i>Contemporary Clinical Trials</i> , 2016, 47, 304-314. | 0.8 | 22 |
| 31 | Nanoformulated copper/zinc superoxide dismutase attenuates vascular cell activation and aortic inflammation in obesity. <i>Biochemical and Biophysical Research Communications</i> , 2016, 469, 495-500. | 1.0 | 17 |
| 32 | Abstract 213: Differential Effects of Nanoformulated Copper/zinc Superoxide Dismutase in Regulating Fasting Blood Glucose Levels in Mice Fed a Low versus High Fat Diet. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, . | 1.1 | 0 |
| 33 | Hematopoietic cyclooxygenase-2 deficiency increases adipose tissue inflammation and adiposity in obesity. <i>Obesity</i> , 2015, 23, 2037-2045. | 1.5 | 6 |
| 34 | Glycated Albumin at 4 Weeks Correlates with A1C Levels at 12 Weeks and Reflects Short-Term Glucose Fluctuations. <i>Endocrine Practice</i> , 2015, 21, 1195-1203. | 1.1 | 27 |
| 35 | Cardiometabolic Effects of a New Class of Antidiabetic Agents. <i>Clinical Therapeutics</i> , 2015, 37, 1178-1194. | 1.1 | 39 |
| 36 | Inpatient Hypoglycemia: A Challenge That Must Be Addressed. <i>Current Diabetes Reports</i> , 2014, 14, 445. | 1.7 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Does drug therapy reverse endothelial progenitor cell dysfunction in diabetes?. Journal of Diabetes and Its Complications, 2013, 27, 519-525. | 1.2 | 35 |
| 38 | Role of apathy in the effectiveness of weight management programmes. Diabetes, Obesity and Metabolism, 2012, 14, 419-423. | 2.2 | 16 |
| 39 | Role of Inflammation and Insulin Resistance in Endothelial Progenitor Cell Dysfunction. Diabetes, 2011, 60, 1286-1294. | 0.3 | 61 |
| 40 | CARDIAC RYANODINE RECEPTOR ACQUIRES A GAIN OF FUNCTION PHENOTYPE DURING TYPE 1 DIABETES. FASEB Journal, 2011, 25, 1112.13. | 0.2 | 0 |
| 41 | Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review. Clinical Medicine Insights: Endocrinology and Diabetes, 2010, 3, CMED.S5372. | 1.0 | 21 |
| 42 | Effects of Salsalate Therapy on Recovery From Vascular Injury in Female Zucker Fatty Rats. Diabetes, 2010, 59, 3240-3246. | 0.3 | 20 |
| 43 | Hypoglycemia, Diabetes, and Cardiovascular Events. Diabetes Care, 2010, 33, 1389-1394. | 4.3 | 374 |
| 44 | The effect of group clinics in the control of diabetes. Primary Care Diabetes, 2010, 4, 251-254. | 0.9 | 5 |
| 45 | Effects of a PPAR-gamma agonist, on growth factor and insulin stimulated endothelial cells. Vascular Pharmacology, 2009, 51, 162-168. | 1.0 | 9 |
| 46 | Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nature Reviews Drug Discovery, 2009, 8, 361-367. | 21.5 | 39 |
| 47 | Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2009, 2, 165. | 1.1 | 5 |
| 48 | Does pioglitazone reduce carotid intima-media thickness in patients with type 2 diabetes mellitus?. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 394-395. | 2.9 | 0 |
| 49 | Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats. Vascular Pharmacology, 2007, 46, 188-194. | 1.0 | 13 |
| 50 | Neointimal hyperplasia and vascular endothelial growth factor expression are increased in normoglycemic, insulin resistant, obese fatty rats. Atherosclerosis, 2006, 184, 283-289. | 0.4 | 18 |
| 51 | Association of Hypoglycemia and Cardiac Ischemia: A study based on continuous monitoring. Diabetes Care, 2003, 26, 1485-1489. | 4.3 | 341 |
| 52 | Differential Effects of Peroxisome Proliferator Activator Receptor- α and β Ligands on Intimal Hyperplasia After Balloon Catheter-Induced Vascular Injury in Zucker Rats. Journal of Cardiovascular Pharmacology and Therapeutics, 2003, 8, 297-305. | 1.0 | 38 |
| 53 | Differential impact of glycemic control and comorbid conditions on the neurophysiology underlying task switching in older adults with type 2 diabetes. Aging, 0, , . | 1.4 | 0 |